Marshall Wace’s Bionano Genomics BNGO Stock Holding History

Marshall Wace’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-709	Closed	-$1.27M	–	3371
2021 Q4	$1.27M	Buy	+709	New	+$1.9M	﹤0.01%	2353

Other funds holding BNGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Marshall Wace's BNGO Position: Q1 2022 in Review

Marshall Wace sold out of Bionano Genomics (BNGO) in Q1 2022, closing a stake of 709 shares — an estimated $1.27M sold.

Marshall Wace first reported a position in BNGO in Q4 2021 and held it in 1 quarter. The position peaked at $1.27M in Q4 2021. 148 funds tracked by Wall St. Rank hold BNGO as of Q1 2022.

Marshall Wace reported no remaining Bionano Genomics position as of Q1 2022 after selling out during the quarter.
Marshall Wace sold 709 Bionano Genomics shares in Q1 2022, an estimated $1.27M.
Marshall Wace first reported a position in Bionano Genomics in Q4 2021 and held it in 1 quarter.
Marshall Wace's Bionano Genomics position peaked at $1.27M in Q4 2021.
148 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.